{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T00:58:34Z","timestamp":1793149114932,"version":"4.5.0"},"reference-count":67,"publisher":"Ovid Technologies (Wolters Kluwer Health)","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:p>Metabolic-associated steatotic liver disease (MASLD), formerly known as nonalcoholic fatty liver disease, is prevalent worldwide and is highly associated with cardiovascular disease (CVD). Lean MASLD is defined by hepatic steatosis and cardiometabolic risk factors in individuals with a body mass index below 25 in Western populations or below 23 in Asian populations. Paradoxically, some studies indicate that lean MASLD is associated with an elevated risk of cardiovascular (CV) disease and CV mortality compared with nonlean MASLD. Lean MASLD patients exhibit distinctive metabolic, genetic, and microbiome profiles contributing to increased visceral adiposity, sarcopenia, hepatic fibrosis, systemic inflammation, and endothelial dysfunction. This review examines the epidemiology, pathophysiology, and CV outcomes associated with lean MASLD, addressing discrepancies in the literature. Furthermore, it highlights current clinical guidelines, emphasizes lifestyle modifications, and discusses emerging pharmacotherapies as potential treatment options.<\/jats:p>","DOI":"10.1097\/crd.0000000000000893","type":"journal-article","created":{"date-parts":[[2025,3,22]],"date-time":"2025-03-22T18:07:24Z","timestamp":1742666844000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":12,"title":["Lean MASLD and Cardiovascular Disease: A Review"],"prefix":"10.1097","author":[{"given":"Nachum","family":"Lebovics","sequence":"first","affiliation":[{"name":"Department of Medicine, NYC Health & Hospitals\/Jacobi Medical Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel","family":"Heering","sequence":"additional","affiliation":[{"name":"Department of Medicine, Westchester Medical Center Health Network, Valhalla, NY."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William H.","family":"Frishman","sequence":"additional","affiliation":[{"name":"Department of Medicine, Westchester Medical Center Health Network, Valhalla, NY."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Lebovics","sequence":"additional","affiliation":[{"name":"Department of Medicine, Westchester Medical Center Health Network, Valhalla, NY."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,3,21]]},"reference":[{"key":"R1-20250321","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/hep.29367","article-title":"The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases.","volume":"67","author":"Chalasani","year":"2018","journal-title":"Hepatology"},{"key":"R2-20250321","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1097\/HEP.0000000000000520","article-title":"A multisociety Delphi consensus statement on new fatty liver disease nomenclature.","volume":"78","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"key":"R3-20250321","doi-asserted-by":"crossref","first-page":"101182","DOI":"10.1016\/j.aohep.2023.101182","article-title":"Insulin resistance and Metabolic dysfunction-associated steatotic liver disease (MASLD): pathways of action of hypoglycemic agents.","volume":"29","author":"Maldonado-Rojas","year":"2024","journal-title":"Ann Hepatol"},{"key":"R4-20250321","doi-asserted-by":"crossref","first-page":"e89","DOI":"10.1016\/j.jhep.2023.10.032","article-title":"MASLD screening and diagnostic algorithms are interchangeable with existing NAFLD literature.","volume":"80","author":"Arora","year":"2024","journal-title":"J Hepatol"},{"key":"R5-20250321","doi-asserted-by":"crossref","first-page":"278","DOI":"10.3390\/jcm13010278","article-title":"What is new in metabolic dysfunction-associated steatotic liver disease in lean individuals: from bench to bedside.","volume":"13","author":"Danpanichkul","year":"2024","journal-title":"J Clin Med"},{"key":"R6-20250321","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1111\/jgh.15156","article-title":"Global epidemiology of lean non-alcoholic fatty liver disease: a systematic review and meta-analysis.","volume":"35","author":"Lu","year":"2020","journal-title":"J Gastroenterol Hepatol"},{"key":"R7-20250321","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.jceh.2021.06.011","article-title":"Lean fatty liver disease: through thick and thin.","volume":"11","author":"Premkumar","year":"2021","journal-title":"J Clin Exp Hepatol"},{"key":"R8-20250321","doi-asserted-by":"crossref","first-page":"757","DOI":"10.3390\/ijerph21060757","article-title":"Advantages and limitations of the body mass index (BMI) to assess adult obesity.","volume":"21","author":"Wu","year":"2024","journal-title":"Int J Environ Res Public Health"},{"issue":"Suppl","key":"R9-20250321","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.3350\/cmh.2022.0365","article-title":"Global incidence and prevalence of nonalcoholic fatty liver disease.","volume":"29","author":"Teng","year":"2023","journal-title":"Clin Mol Hepatol"},{"key":"R11-20250321","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1097\/MPG.0000000000001974","article-title":"Prevalence of suspected nonalcoholic fatty liver disease in lean adolescents in the United States.","volume":"67","author":"Conjeevaram Selvakumar","year":"2018","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"R12-20250321","doi-asserted-by":"crossref","first-page":"197","DOI":"10.7570\/jomes23052","article-title":"Metabolic dysfunction-associated steatotic liver disease (MASLD): a state-of-the-art review.","volume":"32","author":"Chan","year":"2023","journal-title":"J Obes Metab Syndr"},{"key":"R13-20250321","doi-asserted-by":"crossref","first-page":"15473","DOI":"10.3390\/ijms242015473","article-title":"Metabolic-dysfunction-associated steatotic liver disease\u2014its pathophysiology, association with atherosclerosis and cardiovascular disease, and treatments.","volume":"24","author":"Yanai","year":"2023","journal-title":"Int J Mol Sci"},{"key":"R14-20250321","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1111\/jgh.16049","article-title":"Epidemiology and prevalence of lean nonalcoholic fatty liver disease and associated cirrhosis, hepatocellular carcinoma, and cardiovascular outcomes in the United States: a population-based study and review of literature.","volume":"38","author":"Almomani","year":"2023","journal-title":"J Gastroenterol Hepatol"},{"key":"R15-20250321","doi-asserted-by":"crossref","first-page":"154112","DOI":"10.1016\/j.prp.2022.154112","article-title":"Non-alcoholic fatty liver disease (NAFLD) in lean individuals\u2014single centre large cohort clinicopathologic and immunophenotypic study.","volume":"238","author":"Rastogi","year":"2022","journal-title":"Pathol Res Pract"},{"key":"R16-20250321","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.cld.2023.01.011","article-title":"Special population: lean nonalcoholic fatty liver disease.","volume":"27","author":"Duseja","year":"2023","journal-title":"Clin Liver Dis"},{"key":"R17-20250321","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s11154-020-09621-1","article-title":"Lean NAFLD: an underrecognized and challenging disorder in medicine.","volume":"22","author":"Maier","year":"2021","journal-title":"Rev Endocr Metab Disord"},{"key":"R18-20250321","doi-asserted-by":"crossref","first-page":"e0352","DOI":"10.1097\/HC9.0000000000000352","article-title":"The changing epidemiology of adult liver transplantation in the United States in 2013-2022: the dominance of metabolic dysfunction\u2013associated steatotic liver disease and alcohol-associated liver disease.","volume":"8","author":"Younossi","year":"2024","journal-title":"Hepatol Commun"},{"key":"R19-20250321","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1097\/HEP.0000000000000329","article-title":"Lean individuals with NAFLD have more severe liver disease and poorer clinical outcomes (NASH-CO Study).","volume":"78","author":"Nabi","year":"2023","journal-title":"Hepatology"},{"key":"R20-20250321","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/liv.15763","article-title":"Gastrointestinal cancers in lean individuals with non-alcoholic fatty liver disease: a systematic review and meta-analysis.","volume":"44","author":"Souza","year":"2024","journal-title":"Liver Int"},{"key":"R21-20250321","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1186\/s12944-024-02108-x","article-title":"Updated mechanisms of MASLD pathogenesis.","volume":"23","author":"Li","year":"2024","journal-title":"Lipids Health Dis"},{"key":"R22-20250321","doi-asserted-by":"crossref","first-page":"448","DOI":"10.3389\/fmed.2020.00448","article-title":"Non-alcoholic fatty liver disease and alcohol-related liver disease: two intertwined entities.","volume":"7","author":"Idalsoaga","year":"2020","journal-title":"Front Med"},{"key":"R23-20250321","doi-asserted-by":"crossref","first-page":"e00326","DOI":"10.14309\/ctg.0000000000000326","article-title":"Nonalcoholic fatty liver disease in lean subjects: associations with metabolic dysregulation and cardiovascular risk-a single-center cross-sectional study.","volume":"12","author":"Semmler","year":"2021","journal-title":"Clin Transl Gastroenterol"},{"key":"R24-20250321","doi-asserted-by":"crossref","first-page":"2229139","DOI":"10.1155\/2022\/2229139","article-title":"The association of sarcopenia and visceral obesity with lean nonalcoholic fatty liver disease in Chinese patients with type 2 diabetes mellitus.","volume":"2022","author":"Zhang","year":"2022","journal-title":"J Diabetes Res"},{"key":"R25-20250321","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1111\/apt.14112","article-title":"Systematic review with meta-analysis: risk factors for non-alcoholic fatty liver disease suggest a shared altered metabolic and cardiovascular profile between lean and obese patients.","volume":"46","author":"Sookoian","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"R26-20250321","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/ajg.2016.318","article-title":"Clinical and metabolic characterization of lean Caucasian subjects with non-alcoholic fatty liver.","volume":"112","author":"Feldman","year":"2017","journal-title":"Am J Gastroenterol"},{"key":"R27-20250321","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1002\/hep.23832","article-title":"A common variant in the patatin-like phospholipase 3 gene (PNPLA3) is associated with fatty liver disease in obese children and adolescents.","volume":"52","author":"Santoro","year":"2010","journal-title":"Hepatology"},{"key":"R28-20250321","doi-asserted-by":"crossref","first-page":"1217249","DOI":"10.3389\/fendo.2023.1217249","article-title":"Lean nonalcoholic fatty liver disease and sarcopenia.","volume":"14","author":"Chen","year":"2023","journal-title":"Front Endocrinol"},{"key":"R29-20250321","doi-asserted-by":"crossref","first-page":"101544","DOI":"10.1016\/j.aohep.2024.101544","article-title":"Relationship between sarcopenia and metabolic dysfunction-associated steatotic liver disease (MASLD): a systematic review and meta-analysis.","volume":"29","author":"Malik","year":"2024","journal-title":"Ann Hepatol"},{"key":"R30-20250321","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1002\/hep4.1519","article-title":"Prevalence and profile of nonalcoholic fatty liver disease in lean adults: systematic review and meta-analysis.","volume":"4","author":"Young","year":"2020","journal-title":"Hepatol Commun"},{"key":"R31-20250321","doi-asserted-by":"crossref","first-page":"e147","DOI":"10.1016\/j.jhep.2023.11.015","article-title":"Beyond body weight: diversified presentation of MASLD in lean, overweight, and obese participants.","volume":"80","author":"Fan","year":"2024","journal-title":"J Hepatol"},{"key":"R32-20250321","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1007\/s11892-024-01542-6","article-title":"Metabolic dysfunction-associated steatotic liver disease and atherosclerosis.","volume":"24","author":"Castillo-N\u00fa\u00f1ez","year":"2024","journal-title":"Curr Diab Rep"},{"key":"R33-20250321","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1038\/ajg.2015.235","article-title":"Prevalence and severity of nonalcoholic fatty liver disease in non-obese patients: a population study using proton-magnetic resonance spectroscopy.","volume":"110","author":"Wei","year":"2015","journal-title":"Am J Gastroenterol"},{"key":"R34-20250321","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1016\/j.cgh.2017.04.045","article-title":"Liver and cardiovascular damage in patients with lean nonalcoholic fatty liver disease, and association with visceral obesity.","volume":"15","author":"Fracanzani","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R35-20250321","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.3748\/wjg.v26.i15.1792","article-title":"Prevalence, clinical characteristics, risk factors, and indicators for lean Chinese adults with nonalcoholic fatty liver disease.","volume":"26","author":"Zeng","year":"2020","journal-title":"World J Gastroenterol"},{"key":"R36-20250321","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1111\/apt.13169","article-title":"PNPLA3 rs738409 I748M is associated with steatohepatitis in 434 non-obese subjects with hepatitis C.","volume":"41","author":"Petta","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"key":"R37-20250321","doi-asserted-by":"crossref","first-page":"100744","DOI":"10.1016\/j.jhepr.2023.100744","article-title":"Genetic variants in HFE are associated with non-alcoholic fatty liver disease in lean individuals.","volume":"5","author":"Sun","year":"2023","journal-title":"JHEP Rep"},{"key":"R38-20250321","doi-asserted-by":"crossref","first-page":"C319","DOI":"10.1152\/ajpcell.00103.2018","article-title":"MFehi adipose tissue macrophages compensate for tissue iron perturbations in mice.","volume":"315","author":"Hubler","year":"2018","journal-title":"Am J Physiol Cell Physiol"},{"key":"R39-20250321","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1186\/s12967-024-05478-z","article-title":"Polygenic risk score of metabolic dysfunction-associated steatotic liver disease amplifies the health impact on severe liver disease and metabolism-related outcomes.","volume":"22","author":"Xiao","year":"2024","journal-title":"J Transl Med"},{"key":"R40-20250321","doi-asserted-by":"crossref","first-page":"100692","DOI":"10.1016\/j.jhepr.2023.100692","article-title":"Genomic analysis of lean individuals with NAFLD identifies monogenic disorders in a prospective cohort study.","volume":"5","author":"Zheng","year":"2023","journal-title":"JHEP Rep"},{"key":"R41-20250321","doi-asserted-by":"crossref","first-page":"105905","DOI":"10.1016\/j.isci.2022.105905","article-title":"Diet-induced gut dysbiosis and inflammation: key drivers of obesity-driven NASH.","volume":"26","author":"Kang","year":"2023","journal-title":"iScience"},{"key":"R42-20250321","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1097\/MIB.0000000000000750","article-title":"Current understanding of dysbiosis in disease in human and animal models.","volume":"22","author":"DeGruttola","year":"2016","journal-title":"Inflamm Bowel Dis"},{"key":"R43-20250321","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1002\/hep.30908","article-title":"Lean NAFLD: a distinct entity shaped by differential metabolic adaptation.","volume":"71","author":"Chen","year":"2020","journal-title":"Hepatology"},{"key":"R44-20250321","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.numecd.2017.10.014","article-title":"Gut microbiome composition in lean patients with NASH is associated with liver damage independent of caloric intake: a prospective pilot study.","volume":"28","author":"Duarte","year":"2018","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"R45-20250321","doi-asserted-by":"crossref","first-page":"100987","DOI":"10.1016\/j.jhepr.2023.100987","article-title":"Microbiota modulation by dietary oat beta-glucan prevents steatotic liver disease progression.","volume":"6","author":"Jaeger","year":"2024","journal-title":"JHEP Rep"},{"key":"R46-20250321","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1002\/hep4.1534","article-title":"Mortality of NAFLD according to the body composition and presence of metabolic abnormalities.","volume":"4","author":"Golabi","year":"2020","journal-title":"Hepatol Commun"},{"key":"R47-20250321","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1111\/joim.13069","article-title":"Prevalence, characteristics and mortality outcomes of obese, nonobese and lean NAFLD in the United States, 1999-2016.","volume":"288","author":"Zou","year":"2020","journal-title":"J Intern Med"},{"key":"R48-20250321","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1111\/apt.15660","article-title":"Advanced fibrosis is associated with incident cardiovascular disease in patients with non-alcoholic fatty liver disease.","volume":"51","author":"Henson","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"key":"R49-20250321","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1002\/hep.29085","article-title":"Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: systematic review and meta-analysis.","volume":"65","author":"Dulai","year":"2017","journal-title":"Hepatology"},{"key":"R50-20250321","doi-asserted-by":"crossref","first-page":"101643","DOI":"10.1016\/j.cpcardiol.2023.101643","article-title":"Cardiovascular morbidity and mortality related to non-alcoholic fatty liver disease: a systematic review and meta-analysis.","volume":"48","author":"Bisaccia","year":"2023","journal-title":"Curr Probl Cardiol"},{"key":"R51-20250321","doi-asserted-by":"crossref","first-page":"102569","DOI":"10.1016\/j.cpcardiol.2024.102569","article-title":"Cardiovascular morbidity and mortality in lean vs. non-lean MASLD: a comprehensive meta-analysis.","volume":"49","author":"Nso","year":"2024","journal-title":"Curr Probl Cardiol"},{"key":"R52-20250321","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1161\/CIRCULATIONAHA.123.064071","article-title":"Sarcopenia and cardiovascular diseases.","volume":"147","author":"Damluji","year":"2023","journal-title":"Circulation"},{"key":"R53-20250321","doi-asserted-by":"crossref","first-page":"102575","DOI":"10.1016\/j.cpcardiol.2024.102575","article-title":"Lean MASLD: are overweight or obese people with MASLD \u201cprotected\u201d from CVD mortality?","volume":"49","author":"Lima","year":"2024","journal-title":"Curr Probl Cardiol"},{"key":"R54-20250321","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1136\/gutjnl-2020-322564","article-title":"Caucasian lean subjects with non-alcoholic fatty liver disease share long-term prognosis of non-lean: time for reappraisal of BMI-driven approach?","volume":"71","author":"Younes","year":"2022","journal-title":"Gut"},{"key":"R55-20250321","doi-asserted-by":"crossref","first-page":"620","DOI":"10.14309\/ajg.0000000000000074","article-title":"Alcoholic and nonalcoholic fatty liver disease and liver-related mortality: a cohort study.","volume":"114","author":"Chang","year":"2019","journal-title":"Am J Gastroenterol"},{"key":"R56-20250321","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1111\/apt.17424","article-title":"Higher mortality among lean patients with non-alcoholic fatty liver disease despite fewer metabolic comorbidities.","volume":"57","author":"Wijarnpreecha","year":"2023","journal-title":"Aliment Pharmacol Ther"},{"key":"R57-20250321","doi-asserted-by":"crossref","first-page":"290","DOI":"10.5009\/gnl210084","article-title":"Cardiovascular risk is elevated in lean subjects with nonalcoholic fatty liver disease.","volume":"16","author":"Kim","year":"2022","journal-title":"Gut Liver"},{"key":"R58-20250321","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1186\/s12933-022-01648-9","article-title":"Non-obese NAFLD had no better cardio-metabolic risk profile than obese NAFLD in type 2 diabetic patients.","volume":"21","author":"Zhang","year":"2022","journal-title":"Cardiovasc Diabetol"},{"key":"R59-20250321","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1002\/hep4.1818","article-title":"Risk of cardiovascular disease in individuals with nonobese nonalcoholic fatty liver disease.","volume":"6","author":"Arvind","year":"2021","journal-title":"Hepatol Commun"},{"key":"R60-20250321","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1007\/s00535-024-02093-z","article-title":"Natural history of lean and non-lean metabolic dysfunction-associated steatotic liver disease.","volume":"59","author":"Wakabayashi","year":"2024","journal-title":"J Gastroenterol"},{"key":"R61-20250321","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1053\/j.gastro.2022.06.023","article-title":"AGA clinical practice update: diagnosis and management of nonalcoholic fatty liver disease in lean individuals: expert review.","volume":"163","author":"Long","year":"2022","journal-title":"Gastroenterology"},{"key":"R62-20250321","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1053\/j.gastro.2023.06.013","article-title":"AGA clinical practice update on the role of noninvasive biomarkers in the evaluation and management of nonalcoholic fatty liver disease: expert review.","volume":"165","author":"Wattacheril","year":"2023","journal-title":"Gastroenterology"},{"key":"R63-20250321","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1016\/j.jhep.2018.08.011","article-title":"Beneficial effects of lifestyle intervention in non-obese patients with non-alcoholic fatty liver disease.","volume":"69","author":"Wong","year":"2018","journal-title":"J Hepatol"},{"key":"R64-20250321","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJMoa2309000","article-title":"A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis.","volume":"390","author":"Harrison","year":"2024","journal-title":"N Engl J Med"},{"key":"R65-20250321","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1056\/NEJMoa2401943","article-title":"Tirzepatide for metabolic dysfunction\u2013associated steatohepatitis with liver fibrosis.","volume":"391","author":"Loomba","year":"2024","journal-title":"N Engl J Med"},{"key":"R66-20250321","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa2401755","article-title":"A phase 2 randomized trial of survodutide in MASH and fibrosis.","volume":"391","author":"Sanyal","year":"2024","journal-title":"N Engl J Med"},{"key":"R67-20250321","doi-asserted-by":"crossref","first-page":"156043","DOI":"10.1016\/j.metabol.2024.156043","article-title":"Comparative efficacy of THR-\u03b2 agonists, FGF-21 analogues, GLP-1R agonists, GLP-1-based polyagonists, and Pan-PPAR agonists for MASLD: a systematic review and network meta-analysis.","volume":"161","author":"Lin","year":"2024","journal-title":"Metabolism"},{"key":"R68-20250321","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1016\/j.jhep.2023.07.004","article-title":"Treating NASH by targeting peroxisome proliferator-activated receptors.","volume":"79","author":"Staels","year":"2023","journal-title":"J Hepatol"}],"container-title":["Cardiology in Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/CRD.0000000000000893","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T16:29:10Z","timestamp":1786033750000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/CRD.0000000000000893"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,21]]},"references-count":67,"URL":"https:\/\/doi.org\/10.1097\/crd.0000000000000893","relation":{},"ISSN":["1538-4683"],"issn-type":[{"value":"1538-4683","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,21]]}}}